Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 50 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Wesam B.

Sweden

USD 50 /hr

PhD Oncology Scientist | In Vivo Study Design, FFPE/IHC Troubleshooting & Spatial Data Interpretation

Profile Summary

I am a PhD-trained oncology scientist with over 9 years of experience in translational cancer research, in vivo models, and molecular assay development. I help biotech and academic teams design, optimize, and interpret preclinical studies, with a focus on FFPE/IHC, in vivo efficacy models, and robust lab workflows. How I can help you: • In vivo study design & interpretation – dosing schedules, endpoints, sample collection, and mechanistic readouts in oncology models. • FFPE / IHC troubleshooting & optimization – panel setup, staining workflows, basic image analysis strategy, and result interpretation. • Assay development support – design and refinement of in vitro assays (e.g. viability, pathway readouts, PROTAC MoA) to answer clear biological questions. • Lab workflows & documentation – SOP development, QC checklists, experimental templates, and documentation to improve reproducibility and turnaround. • Spatial biology data interpretation (theoretical) – high-level review and biological interpretation of spatial or multiplex imaging datasets (not platform setup or coding). My experience includes >50 in vivo oncology studies, >30 optimized in vitro assays, and review/analysis of >1000 FFPE samples. I’m used to collaborating with multidisciplinary teams and clearly communicating complex findings to scientists and non-scientists. Clients work with me when they need a scientist who can quickly understand the biological question, design practical experiments, and provide clear, actionable interpretations rather than just raw data. Example projects I can support: • Design of an in vivo oncology efficacy study (including rationale and endpoints) • Troubleshooting poor IHC/IF staining on FFPE samples • Drafting or refining SOPs for sample processing or biomarker workflows • Reviewing preclinical data package and summarizing key findings for internal presentations

Subject Matter Expertise

• ★ Molecular Biology
• ★ Preclinical Research
• ★ Cancer Research
• ☆ Drug Discovery
• ☆ Drug Target Identification
• ☆ Drug Development
• ☆ Medical Sciences
• ☆ Research Summaries & Abstracts

Services

• Writing
• Research
• Consulting
• Data & AI
• Product Development

Writing Medical Writing, General Proofreading & Editing, Translation

Research Feasibility Study, Fact Checking, Scientific and Technical Research

Consulting Scientific and Technical Consulting

Data & AI Statistical Analysis, Image Processing, Image Analysis, Data Visualization

Product Development Quality Assurance & Control (QA/QC)

Work Experience

Researcher

Uppsala University

March 2024 - Present

Senior Scientist

MyCural Therapeutics AB

November 2022 - Present

Postdoctoral Researcher

Radiumhemmets Forskningsfonder

July 2021 - June 2022

Education

Ph.D (Microbiology, Tumor and Cell Biology (MTC))

Karolinska Institutet

September 2014 - June 2021

MSc Biomedical Sciences

Uppsala University

September 2011 - June 2013

Masters of Science

Örebro University - Sweden

September 2009 - June 2011

Certifications

• Certified Pharmaceutical GMP Professional

  Svensk Medicin AB

  December 2021 - Present

• Essentials of regulatory affairs (RA) and good distribution practices (GDP)

  Svensk Medicin AB

  November 2021 - Present

Publications

PREPRINT

Wesam Bazzar, Fan Zhang, Lola Boutin, Ishani Das, Jeroen Melief, Madhurendra Singh, Marina Stantic, Mohammad Alzrigat, Alireza Azimi, Lucas Baldran, et al. (2025). Palbociclib CDK4/6- and Crizotinib MET/ALK/ROS1-inhibitors Synergize to Enhance Senescence and Immune Recognition in Melanoma Cells Independently of <i>BRAF</i>/<i>NRAS</i> Status .

JOURNAL ARTICLE

Agarwal P, Glowacka A, Mahmoud L, Bazzar W, Larsson LG, Alzrigat M (2023). MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma . International journal of molecular sciences.

Agarwal, P., Glowacka, A., Mahmoud, L., Bazzar, W., Larsson, L.-G., Alzrigat, M.(2023). MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma . International Journal of Molecular Sciences. 24. (9).

Castell A, Yan Q, Fawkner K, Bazzar W, Zhang F, Wickstr&#246;m M, Alzrigat M, Franco M, Krona C, Cameron DP, et al. (2022). MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner . Cancer research communications.

Castell, A., Yan, Q., Fawkner, K., Bazzar, W., Zhang, F., Wickstr&#246;m, M., Alzrigat, M., Franco, M., Krona, C., Cameron, D.P., et al.(2022). MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner . Cancer Research Communications. 2. (3). p. 182-201.

Zhang F, Bazzar W, Alzrigat M, Larsson LG (2021). Methods to Study Myc-Regulated Cellular Senescence: An Update . Methods in molecular biology (Clifton, N.J.).

Bazzar, W., Bocci, M., Hejll, E., H&#246;gqvist Tabor, V., Hydbring, P., Grandien, A., Alzrigat, M., Larsson, L.-G.(2021). Pharmacological inactivation of CDK2 inhibits MYC/BCL-XL-driven leukemia in vivo through induction of cellular senescence . Cell Cycle. 20. (1). p. 23-38.

Bazzar W, Bocci M, Hejll E, H&#246;gqvist Tabor V, Hydbring P, Grandien A, Alzrigat M, Larsson LG (2020). Pharmacological inactivation of CDK2 inhibits MYC/BCL-XL-driven leukemia in vivo through induction of cellular senescence . Cell cycle (Georgetown, Tex.).

Castell A, Yan Q, Fawkner K, Hydbring P, Zhang F, Verschut V, Franco M, Zakaria SM, Bazzar W, Goodwin J, et al. (2018). A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation . Scientific reports.

Castell, A., Yan, Q., Fawkner, K., Hydbring, P., Zhang, F., Verschut, V., Franco, M., Zakaria, S.M., Bazzar, W., Goodwin, J., et al.(2018). A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation . Scientific Reports. 8. (1).

Langenkamp E, Zhang L, Lugano R, Huang H, Elhassan TE, Georganaki M, Bazzar W, L&#246;&#246;f J, Trendelenburg G, Essand M, et al. (2015). Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival . Cancer research.

Langenkamp, E., Zhang, L., Lugano, R., Huang, H., Elhassan, T.E.A., Georganaki, M., Bazzar, W., L&#246;&#246;f, J., Trendelenburg, G., Essand, M., et al.(2015). Elevated expression of the C-Type Lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival . Cancer Research. 75. (21). p. 4504-4516.

BOOK CHAPTER

Zhang, F., Bazzar, W., Alzrigat, M., Larsson, L.-G.(2021). Methods to study myc-regulated cellular senescence: an update . Methods in Molecular Biology. 2318. p. 241-254.